Inhibitory effect of curcumin on mammalian phospholipase D activity  by Yamamoto, Hisanori et al.
FEBS Letters 417 (1997) 196-198 FEBS 19428 
Inhibitory effect of curcumin on mammalian phospholipase D activity 
Hisanori Yamamotoa'b, Kentaro Hanadaa,b, Kiyoshi Kawasakia, Masahiro Nishijimaa'* 
aDepartment of Biochemistry and Cell Biology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan 
b CREST, Japan Science and Technology Corporation, Tokyo, Japan 
Received 5 September 1997; revised version received 6 October 1997 
Abstract Curcumin, the major yellow pigment of turmeric 
{Curcuma longa), has strong anti-carcinogenic and anti-inflam-
matory activities. We examined the effects of curcumin on 
enzyme activities of the following phospholipases in a cell-free 
system: G protein-mediated phospholipase D (PLD), phospha-
tidylinositol-specific phospholipase C, and phospholipase A 2 
from mouse macrophage-like cell line J774.1 cells, sphingomye-
linase from bovine brain, and phosphatidylcholine-phospholipase 
C from Bacillus cereus. Curcumin inhibited several types of 
phospholipases, most effectively PLD among those tested. It also 
inhibited 12-0-tetradecanoylphorbol-13-acetate-induced P L D 
activation in intact J774.1 cells in a dose-dependent manner. 
These results suggest that the anti-inflammatory and anti-
carcinogenic action of curcumin is partly due to the inhibition of 
PLD. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Curcumin is the major pigment in turmeric, the powdered 
rhizome of Curcuma longa, which is widely used for the treat-
ment of a variety of inflammatory conditions and other dis-
eases [1]. Recent studies have shown that curcumin possesses 
anti-oxidant and anti-inflammatory activities [2-6]. Curcumin 
potently inhibits the initiation and promot ion of chemical 
carcinogen-induced tumor formation in mice [7,8] and the 
proliferation of animal epithelial and muscle cells [9,10]. It 
also inhibits the 12-0-tetradecanoylphorbol-13-acetate 
(TPA)-mediated induction of c-Jun/AP-1 [11] and protein kin-
ase C (PKC) activity [12] in mouse NIH/3T3 cells, induction 
of nitric oxide synthase in activated macrophages [13], T N F -
a/TNF-R-media ted N F - K B activation in human myeloid cells 
[14], and EGF-induced activation of E G F - R phosphorylation 
[15], but it remains unclear what molecule(s) curcumin directly 
modulates in cells. Furthermore, curcumin effectively inhibits 
type 1 human immunodeficiency virus long terminal repeat-
directed gene expression and the virus replication [16]. 
In response to various stimuli, the breakdown of phospho-
lipids plays crucial roles in the early steps of the signaling 
pathways [17]. For example, phospholipase A2 (PLA2) , phos-
phatidylinositol-specific phospholipase C (PI-PLC), and 
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Abbreviations: TPA, 12-0-tetradecanoylphorbol-13-acetate; TNF, tu-
mor necrosis factor; FCS, fetal calf serum (heat-inactivated); PC, 
phosphatidylcholine; PA, phosphatidic acid; PBut, phosphatidyl 
butanol; PC-PLC, PC-specific phospholipase C; PLD, phospholipase 
D; G proteins, guanine-nucleotide binding proteins; ARF, ADP-
ribosylation factor; GTPyS, guanosine 5'-0-[y-thio]triphosphate; 
DMSO, dimethylsulfoxide; PDTC, pyrrolidine dithiocarbamate 
sphingomyelinase (SMase) are involved in various receptor-
mediated signalings [17], and the breakdown of phosphatidyl-
choline (PC) by phospholipase C or D (PC-PLC, PLD) is 
suggested to be involved in the signalings in response to 
TNF-cc and platelet-derived growth factor [18]. In the present 
study, we examined whether curcumin modulated the activ-
ities of these phospholipases and found that it inhibited the 
activities of various phospholipases, most effectively PLD ac-
tivity, in a cell-free system and in intact cells. 
2. Materials and methods 
2.1. Materials 
TPA was purchased from Sigma Chemicals (St. Louis, MO, USA). 
Curcumin was purchased from Wako Pure Chemical (Tokyo, Japan) 
and stored as a 100 mM stock solution in dimethylsulfoxide (DMSO) 
at —30°C under light-shielding conditions. ADP-ribosylation factor 
(ARF) was prepared according to Tanigawa et al. [19]. 
2.2. Cell culture 
Mouse macrophage-like J774.1 cells were maintained in Ham's F-12 
medium supplemented with 10% (v/v) heat-inactivated (56°C, 30 min) 
newborn calf serum (NCS, ICN Biomedicals, CA, USA) at 37°C in a 
water-saturated atmosphere of 5% CO2 in air. 
2.3. Cell-free assays of phospholipases 
J774.1 membranes were prepared according to Hara-Kuge et al. 
[20], and protein concentrations were determined by the method of 
Bradford [21], using bovine serum albumin as the standard. Mem-
branes were preincubated with or without curcumin at 37°C for 30 
min, then the phospholipase reactions were started by addition of 
radioactive phospholipid substrates. Assays were performed at 37°C, 
and lipids were extracted according to Bligh and Dyer [22]. 
For assay of ARF/GTPyS-dependent PLD activity, J774.1 mem-
branes (0.3 mg protein/ml) were incubated with [14C]dipalmitoyl-PC 
(4.2 GBq/mmol, DuPont New England Nuclear, Boston, MA, USA) 
in the presence of 1% butanol [23], and formation of 
[14C]phosphatidylbutanol ([14C]Pbut) was measured [24]. For PI-
PLC assay, J774.1 membranes (0.3 mg protein/ml) were incubated 
with [mvo-inositol-3H]PI (407 GBq/mmol, DuPont New England Nu-
clear), and the release of [3H]inositol was measured [25]. For PLA2 
assay, J774.1 cell lysates (0.3 mg/ml) were incubated with l-acyl-2-
[l-14C]arachidonyl-L-3-phosphatidylethanolamine (2.04 GBq/mmol, 
Amersham, London, UK), and release of [14C]arachidonic acid was 
determined [26]. Since activities of acidic and neutral SMases in J774.1 
membranes were very low, bovine brain cell lysates were used as an 
enzyme source for SMase assays. Neutral and acidic SMase activities 
in bovine brain cell lysates (0.2 mg/ml) were measured according to 
Schiitze et al. [27] by using [me?/fj>/-14C]choline-sphingomyelin (2.04 
GBq/mmol, American Radiolabeled Chemicals Inc., St. Louis, MO) 
as the substrate. Activity of PC-PLC from Bacillus cereus (Boehringer 
Mannheim, 0.4 U/ml) was assayed using [14C]dipalmitoyl-PC as the 
substrate [28]. 
2.4. Effect of curcumin on TPA-induced PLD activity in J774.1 cells 
J774.1 cells (1 X 107 cells) were cultured in 6 ml of F-12 containing 
1% FCS and [14C]palmitate (1.92 GBq/mmol, Moravek Biochemicals 
Inc., CA) at 37°C for 1 day, then harvested by centrifugation (500Xg, 
5 min). The prelabeled cells suspended in F12/0.1% NCS (approxi-
mately 1x10° cells/ml) were incubated with or without curcumin at 
37°C for 30 min. After addition of 1% (v/v) butanol to the cell sus-
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pension, the reaction was started by addition of 100 nM TPA, and 
[14C]PBut formation was measured [24]. 
3. Results 
3.1. Effect of curcumin on activities of various phospholipases 
in cell-free systems 
A membrane fraction prepared from J774.1 cells was used 
as an enzyme source for assays of ARF/GXPyS-dependent 
PLD and PI-PLC, and a cytosol fraction prepared from 
J774.1 cells was used for assay of PLA2. Cell lysates of bovine 
brain were used for assays of acidic and neutral SMases. 
Curcumin potently inhibited ARF/GTPyS-dependent PLD ac-
tivity in a dose-dependent manner (Fig. 1A). The curcumin 
concentration required to inhibit the PLD activities by 50% 
(IC50) was about 10 |J,M, and 50 |J,M curcumin inhibited the 
PLD activity by 80%. Although 10 uM curcumin did not 
affect other phospholipase activities, higher concentrations 
of curcumin substantially inhibited the cytosolic PLA2 activity 
(IC50 = 50 uM) and bacterial PC-PLC activity (IC50 = 80 uM). 
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Fig. 1. Effect of curcumin on phospholipase activities. Sources of 
the indicated enzymes were preincubated with various concentra-
tions of curcumin for 30 min. Then phospholipase assays were 
started by addition of phospholipid substrates to the enzyme sour-
ces, and the activities were determined as described in Section 2. 
The activities after treatment with curcumin are represented as per-
centages of the control activities. The data shown are mean val-
ues ±S.D. of three independent experiments. A: ARF/GTPyS-de-
pendent PLD. B: PC-PLC. C: PI-PLC. D: PLA2. E: Acidic and 
neutral SMases. 
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Fig. 2. TPA-induced PLD activation. A: [14C]palmitate-labeled 
J774.1 cells were stimulated with 100 nM TPA (closed circle) in the 
presence of 1% butanol. The level of [14C]PBut in the absence of 
TPA at 0 min was taken as 1. B: Dose-dependent effect of curcu-
min on PLD activity. [14C]Palmitate-labeled J774.1 cells were incu-
bated with various concentrations of curcumin at 37°C for 30 min, 
then stimulated with 100 nM TPA at 37°C for 20 min. The level of 
[14C]PBut in the presence of TPA without curcumin was taken as 
100%. C: [14C]Palmitate-labeled J774.1 cells were incubated with or 
without 100 uM H-7 and 100 uM PDTC at 37°C for 30 min, then 
stimulated with 100 nM TPA at 37°C for 20 min. The level of 
[14C]PBut in the presence of TPA without drugs was taken as 
100%. The data shown are mean values ± S.D. of three independent 
experiments. 
manner up to 100 |J.M, but the maximum inhibition of PI-
PLC by curcumin was only 50% (Fig. 1C). Curcumin up to 
200 uM did not appreciably inhibit either acidic or neutral 
SMase activity (Fig. IE). These results suggest that curcumin 
inhibited PLD more potently than other phospholipases. 
3.2. Curcumin inhibited TPA-induced PLD activation in intact 
cells 
To examine whether curcumin effectively inhibits PLD ac-
tivity in intact cells, J774.1 cells were labeled with 
[14C]palmitate, then stimulated with 100 nM TPA in the pres-
ence of 1% butanol. As shown in Fig. 2A, significant elevation 
of [14C]PBut level was detectable within 1 min after stimula-
tion, and the accumulation of [14C]PBut reached a maximum 
level at 20 min. When [14C]palmitate-labeled J774.1 cells were 
incubated with various concentrations of curcumin for 30 min 
before stimulation with 100 nM TPA in the presence of 1% 
butanol, the TPA-induced [14C]PBut accumulation was pre-
vented by the curcumin treatment in a dose-dependent man-
ner (Fig. 2B). The IC50 value of curcumin to inhibit the TPA-
induced PLD activation was 35 |0,M, and almost complete 
inhibition was observed at 50 u\M curcumin. 
Since it is known that TPA activates PKC and induces the 
stimulation of oxidative metabolism, that some PLDs are ac-
tivated by PKC and hydrogen peroxide, and that curcumin 
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inhibits PKC catalytic activity and acts as an anti-oxidant, it 
is possible that curcumin may inhibit TPA-induced PLD acti-
vation as a consequence of its inhibitory effect on activation 
of PKC and/or oxidant production by TPA. To test this pos-
sibility, we examined the effects of a PKC inhibitor and an 
anti-oxidant on the TPA-induced PLD activation in J774.1 
cells. Pretreatment of cells with H-7, a potent inhibitor of 
PKC due to competition with ATP for binding to the catalytic 
domain, even at 100 uM, caused only slight inhibition of the 
TPA-induced PLD activation (Fig. 2C). Pyrrolidine dithiocar-
bamate (PDTC), an antioxidant, at 100 |J,M did not affect the 
production of [14C]PBut following TPA stimulation (Fig. 2C). 
These results suggest that the TPA-induced PLD activation 
does not require PKC catalytic activity or oxidative processes 
and that the inhibition of PLD activity by curcumin is not a 
consequence of PKC inhibition or anti-oxidation. 
4. Discussion 
Curcumin is a pharmacologically safe compound with anti-
inflammatory, anti-carcinogenic and free radical scavenger 
properties [1-6]. In this study, we investigated the effects of 
curcumin on the activities of various phospholipases that 
might be involved in signaling pathways. 
We found that curcumin potently inhibited ARF/GTPyS-
dependent PLD activity in membrane fractions of J774.1 cells 
and TPA-induced PLD activity in intact J774.1 cells even at 
low concentrations (10-30 (iM). Several PLDs are activated 
by PKC and small G proteins, such as ARF, Rho, and 
CDC42. It has recently been shown that TPA induces PLD 
activation via modulation of PKC which is independent of 
PKC catalytic activity [29,30]. Our results showed that curcu-
min inhibited both ARF/GTPyS-dependent and TPA/PKC-in-
duced PLD activities, suggesting that the inhibition of PLD 
activity by curcumin is due to a direct interaction of curcumin 
with PLD but not to inhibition, if any, of ARF or PKC by 
curcumin. 
Curcumin moderately inhibited bacterial PC-PLC (IC50 = 80 
uM). Since no cell-free assay system for mammalian PC-PLC 
has been established, we did not address the question of 
whether curcumin inhibited mammalian PC-PLC. But the 
moderate inhibition of bacterial PC-PLC by curcumin sug-
gests that curcumin might also inhibit the putative PC-PLC 
of mammalian cells. Curcumin also inhibited PI-PLC activity 
in a dose-dependent manner up to 100 uM, but higher con-
centrations caused no further increase of inhibition. This pla-
teau level of about 50% inhibition might reflect the presence 
of some PI-PLC isoforms that are inhibited by curcumin and 
others that are not, since PI-PLC is known to possess multiple 
isozyme forms with different properties and different subcel-
lular localizations, including three well-defined groups, PI-
PLC |3, y, and 5 [31]. Curcumin did not appreciably inhibit 
SMase activity even at 200 uM. 
Pretreatment of cells with 40-60 (xM curcumin inhibited 
N F - K B activation by TNF-a in human leukemia cells [14] 
and by LPS in J774.1 cells (our unpublished data). Stimula-
tion with TNF-a or LPS induces diacylglycerol (DAG) pro-
duction from PC, leading to N F - K B activation [28,32]. ras-
dependent transformation of NIH/3T3 cells is also associated 
with elevation of the DAG level via action of PC hydrolysis 
[33]. Our findings that curcumin strongly inhibited PLD ac-
tivity in intact cells as well as in a cell-free system raise the 
possibility that the anti-inflammatory/anti-carcinogenic effects 
of curcumin may be, at least partly, due to the inhibition of 
PLD activity. 
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